Will Pluristem Therapeutics (PSTI) Crush Estimates at Its Next Earnings Report? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Dec 11, 8:01AM CST
Pluristem Therapeutics has seen a nice streak of beating earnings estimates at the previous two reports and might be in a good position to beat earnings at its next report
PSTI: 2.60 (+0.01)
Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.60 (+0.01)
Pluristem and Hadassah Medical Center Will Collaborate to Study Potential of PLX-RAD Cells to Improve Bone Marrow and Umbilical Cord Blood Transplant Outcomes
GlobeNewswire - Thu Dec 04, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.60 (+0.01)
Exelixis Shares Down on COMET-2 Study Results on Cabozantinib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 1:29PM CST
Shares of Exelixis, Inc. (EXEL) dropped 10.2% after the company announced that the trial COMET-2 on cabozantinib did not meet its primary endpoint.
VRX: 138.71 (-0.18), PSTI: 2.60 (+0.01), EXEL: 1.40 (unch)
Pluristem wins patent for 3D cell expansion technology in Singapore
M2 - Mon Dec 01, 7:22AM CST
Cell therapy products company Pluristem Therapeutics (NasdaqCM
PSTI: 2.60 (+0.01)
Pluristem Granted Patent in Singapore for Its 3D Cell Expansion Technology
GlobeNewswire - Mon Dec 01, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.60 (+0.01)
Pluristem's Dr. Ohad Karnieli to Present at Two Upcoming Scientific Conferences
GlobeNewswire - Tue Nov 25, 2:00AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.60 (+0.01)
Pluristem posts 1Q loss
Automated Insights - Fri Nov 21, 6:15AM CST
HAIFA, Israel (AP) _ Pluristem Therapeutics Inc. (PSTI) on Friday reported a loss of $5.9 million, or 9 cents per share, in its fiscal first quarter.
PSTI: 2.60 (+0.01)
Pluristem wins patents in Australia and New Zealand for placental cells for treating orthopedic, nerve injury and neurodegenerative diseases
M2 - Wed Nov 12, 6:25AM CST
Placenta cell therapy company Pluristem Therapeutics (NasdaqCM
PSTI: 2.60 (+0.01)
Pluristem Granted Patents in Australia and New Zealand for Use of Placental Cells in the Treatment of Multiple Indications
GlobeNewswire - Wed Nov 12, 2:35AM CST
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.60 (+0.01)
Pluristem CEO Zami Aberman to Present at Two Regenerative Medicine Conferences in London on November 12 and 13, 2014
GlobeNewswire - Mon Nov 10, 2:00AM CST
London Regenerative Medicine Network Meeting
PSTI: 2.60 (+0.01)
Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014 - 38 Companies & 67 Drug Profiles
M2 - Thu Nov 06, 3:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/rdllgl/graft_versus_host) has announced the addition of the "Graft Versus Host Disease (GVHD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Graft Versus Host Disease (GVHD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Graft Versus Host Disease (GVHD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development (Partial List) - F. Hoffmann-La Roche Ltd. - Biogen Idec Inc. - Athersys, Inc. - Seattle Genetics, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Idera Pharmaceuticals, Inc. - Mesoblast Limited - Jazz Pharmaceuticals plc - Alexion Pharmaceuticals, Inc. - Soligenix, Inc. - NeoStem, Inc. - Pharmacyclics, Inc. - Pluristem Therapeutics Inc. - MediPost Co., Ltd. - Kamada Ltd. - R-Tech Ueno, Ltd. - Omni Bio Pharmaceutical Inc. - Alder Biopharmaceuticals Inc. - MSM Protein Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/rd...ersus_host
BIIB: 344.49 (+2.16), PCYC: 132.65 (-2.34), PSTI: 2.60 (+0.01), NBS: 3.58 (+0.31), ALDR: 25.27 (-1.46), IDRA: 3.84 (-0.03), SGEN: 32.25 (-1.49), JAZZ: 165.12 (-8.09), ALXN: 186.90 (-4.72), KMDA: 3.51 (-0.02), ATHX: 1.36 (+0.05), NVS: 93.52 (-0.82)
Pluristem Therapeutics Developing Off-The-Shelf Cell Therapy to Cure Blood Cancers and Treat Radiation Sickness
ACCESSWIRE - Wed Nov 05, 7:40AM CST
LOS ANGELES, CA / ACCESSWIRE / November 5, 2014 / Innovation is the root of Pluristem Therapeutics's (PSTI:NASDAQ) technology, and its latest offering, PLX-RAD cells represent a new line of allogenic off-the-shelf therapy with two distinct and vital applications - bone marrow transplant (BMT) and acute radiation syndrome (ARS). PLX-RAD cells are specifically engineered to treat blood cancers and restore healthy bone marrow function following chemotherapy, radiation therapy, and radiation exposure resulting from a nuclear or terrorist dirty bomb.
PSTI: 2.60 (+0.01)
The Spectranetics Corporation (SPNC) in Focus: Stock Soars 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:21AM CDT
The Spectranetics Corporation (SPNC) was a big mover last session, as the company saw its shares soar by over 13% on the day.
SPNC: 34.37 (+0.70), VRX: 138.71 (-0.18), PSTI: 2.60 (+0.01), MYL: 53.32 (-1.39)
Case Western Reserve University to Study Pluristem's PLX-RAD Cells in Umbilical Cord Blood Transplants for the Treatment of Blood Cancers and Genetic Diseases
GlobeNewswire - Mon Oct 27, 2:59AM CDT
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.60 (+0.01)
Japan Gives A Hug To The Cell Therapy Industry: R. Lee Buckler
Life Sciences Report - Seeking Alpha - Fri Oct 24, 7:21AM CDT
Last year, Japan rolled out the red carpet for cell therapy developers with new legislation designed to expedite development of regenerative medicine solutions for all manner of disease. In this interview with The Life Sciences Report , former...
PSTI: 2.60 (+0.01), UTHR: 129.37 (-1.86), OSIR: 12.92 (-0.04), ATHX: 1.36 (+0.05)
Alexion Beats on Earnings & Revenues in Q3, Guides Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 12:28PM CDT
Alexion (ALXN) reported higher than expected earnings in the quarter.
MDVN: 106.86 (-1.16), PSTI: 2.60 (+0.01), ALXN: 186.90 (-4.72), PDLI: 7.41 (-0.08)
Celgene Beats Q3 Earnings Estimates on High Revlimid Sales - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 11:50AM CDT
Celgene (CELG) reported higher than expected earnings in the quarter.
MDVN: 106.86 (-1.16), PSTI: 2.60 (+0.01), PDLI: 7.41 (-0.08), CELG: 114.49 (-2.25)
Pluristem Advances Its Second Major Cell Therapy Product Line From Development to Large-Scale Manufacturing
GlobeNewswire - Tue Oct 21, 2:00AM CDT
Pluristem Therapeutics Inc. (Nasdaq
PSTI: 2.60 (+0.01)
Pluristem's Therapy for Muscle and Tendon Regeneration May Revolutionize Sports Medicine
ACCESSWIRE - Fri Oct 17, 7:00AM CDT
Los Angeles, CA / ACCESSWIRE / October 17, 2014 / With football season underway, my thoughts run to player injury and how it keeps good athletes off the field with few options for recovery except the stale advice and medicine doctors offer. Rotator cuff damage is a good example. Surgery is invasive and has serious consequences. Rest and recovery takes months. Whether or not talent will be restored is always a question. Enter the questionable treatments: Regenexx, is a privately-held company pandering to sports superstars with promises of stem cell therapy that can't be substantiated. However, there is an answer - Pluristem (NASDAQ
PSTI: 2.60 (+0.01)